Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis

Rheumatology

Volumn 43, Issue 2, 2004, Pages 143-147

  Saravanan, V ^a,b   Kelly, C A ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GOLD DERIVATIVE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

BRONCHOSCOPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG INDICATION; DRUG WITHDRAWAL; DYSPNEA; HUMAN; LUNG FUNCTION TEST; LUNG LAVAGE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; THORAX RADIOGRAPHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES; METHOTREXATE; PATIENT SELECTION; PNEUMONIA;

EID: 1242342218     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg466     Document Type: Review

References (39)

1. Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centre. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists. J Rheumatol 2001;28: 2201-8.
2. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000;39:975-81.
3. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-19.
4. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis - A national clinical guideline. Publication No. 48. Scottish Intercollegiate Guidelines Network, 2000.
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
6. Howes M, Tose J, White C, Kumar N, Heycock C, Kelly C. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis? Intern Med 1999;7:51-4.
7. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995;22:1043-7.
8. Carroll GJ, Thomas R, Phatouros CC et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994;21: 51-4.
9. Alarcon GS, Kremer JM, Macaluso M et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997;127:356-64.
10. Bartram SA. Experience with methotrexate-associated pneumonitis in northeastern England. Arthritis Rheum 1998;41:1327-8.
11. Ohosone Y, Okano Y, Kameda H et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997;24:2299-303.
12. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933-8.
13. Beyeler C, Jordi B, Gerber NJ, Im H, V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1996;35:446-52.
14. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40: 1829-37.
15. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373-81.
16. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int. 1996;15:195-200.
17. Zisman DA, McCune WJ, Tino G, Lynch JP, III. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:243-52.
18. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994;107:266-70.
19. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosentein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:670-1.
20. Akoun GM, Gauthier-Rahman S, Mayaud CM, Touboul JL, Denis MF. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987;91:96-9.
21. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18-21.
22. Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profile in methotrexate, induced pneumonitis. Thorax 1997;52:377-9.
23. Fuhrman C, Parrot A, Wislez M et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001;164:1186-91.
24. Akoun GM, Mayaud CM, Touboul JL, Denis M. Methotrexate-induced pneumonitis: diagnostic value of bronchoalveolar lavage cell data. Arch Intern Med 1986;146:804-5.
25. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164-71.
26. Padley SP, Adler B, Hansell DM, Muller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992;46:232-6.
27. Suwa A, Hirakata M, Satoh S, Mimori T, Utsumi K, Inada S. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol 1999;17:355-8.
28. Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:272-4.
29. Dawson JK, Desmond J, Graham DR. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 2002;41: 262-7.
30. Saravanan V, Kelly CA. Pulmonary function after methotrexate in rheumatoid arthritis: A one-year follow up study. Rheumatology 2002;41:S145.
31. Khadadah ME, Jayakrishnan B, Al Gorair S et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - a prospective study. Rheumatol Int 2002;22:204-7.
32. Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross WL. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 1996;15:277-82.
33. Scott DG, Bacon PA. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 1980;35:725-32.
34. Joffe MM, Love LA, Leff RL et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-87.
35. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology 2002;41:253-61.
36. Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:308-10.
37. Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med 1998;92:1059-65.
38. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56:622-7.
39. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:t-64.